Buy (150 RUB)
Generate QR code
Open Access
Subscription or Fee Access
Postcovoid syndrome from the perspective of a rheumatologist: problems of differential diagnosis
https://doi.org/10.33667/2078-5631-2025-9-32-36
Abstract
A feature of post-covid syndrome (PCS) as a nosological unit is a wide range of clinical manifestations, which significantly complicates its diagnosis and makes diagnosis possible only after excluding other potential causes. The article discusses symptoms that occur both in PCS and in rheumatic diseases. The authors emphasize the similarities and differences in clinical manifestations in both cases, as well as the methods of diagnosis and monitoring that are found in the literature. The need for a thorough examination of patients with newly occurring symptoms for the timely detection of rheumatic disease is emphasized.
Keywords
post-covid syndrome,
arthritis,
systemic connective tissue diseases,
shortness of breath,
rash,
pericarditis
Supporting agencies: The article was prepared within the framework of the research work of V.A. Nasonova Research Institute of Rheumatology, state assignment number RK 125020301268–4.
About the Authors
E. S. Aronova
V.A. Nasonova Research Institute of Rheumatology, Laboratory of Comorbid Infections and Vaccine Prevention
Russian Federation
Russian Federation
Evgeniya S. Aronova - PhD Med, researcher.
Moscow
B. S. Belov
V.A. Nasonova Research Institute of Rheumatology, Laboratory of Comorbid Infections and Vaccine Prevention
Russian Federation
Russian Federation
Boris S. Belov - DM Sci (habil.), рead of Dept.
Moscow
G. I. Gridneva
V.A. Nasonova Research Institute of Rheumatology, Laboratory of Comorbid Infections and Vaccine Prevention
Russian Federation
Russian Federation
Galina I. Gridneva - PhD Med, researcher.
Moscow
References
1. Rahmati M, Udeh R, Yon DK, et al. A systematic review and meta-analysis of long-term sequelae of COVID-19 2–year after SARS-CoV-2 infection: A call to action for neurological, physical, and psychological sciences. J Med Virol. 2023; 95: e28852. https://doi.org/10.1002/jmv.28852
2. Petersen MS, Kristiansen MF, Hanusson KD. et al. Long COVID in the Faroe Islands – a longitudinal study among non-hospitalized patients. Clin. Infect. Dis. 2021; 73: 11: e4058–e4063. https://doi.org/10.1093/cid/ciaa1792
3. Carvalho-Schneider C, Laurent E, Lemaignen A. et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021; 27 (2): 258–263. DOI: 10.1016/j.cmi.2020.09.052
4. Lopez-Leon S, Wegman-Ostrosky T, Perelman C. et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci Rep. 2021; 11: 16144. https://doi.org/10.1038/s41598-021-95565-86
5. Ghosn J, Piroth L, Epaulard O. et al. Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. Clin Microbiol Infect. 2021; 27 (7): 1041.e1–1041.e4. DOI: 10.1016/j.cmi.2021.03.012
6. Sulewski A, Sieroń D, Szyluk K, Dąbrowski M, Kubaszewski Ł, Lukoszek D, Christe A. Avascular Necrosis Bone Complication after Active COVID-19 Infection: Preliminary Results. Medicina (Kaunas). 2021 Nov 30; 57 (12): 1311. DOI: 10.3390/medicina57121311
7. Baimukhamedov C, Botabekova A, Lessova Z. et al. Osteonecrosis amid the COVID-19 pandemic. Rheumatol Int. 2023; 43 (7): 1377–1378. DOI: 10.1007/s00296-023-05332-3
8. Hassan AAA, Khalifa AA. Femoral head avascular necrosis in COVID-19 survivors: a systematic review. Rheumatol Int. 2023 Sep; 43 (9): 1583–1595. DOI: 10.1007/s00296-023-05373-8
9. Mont MA, Pivec R, Banerjee S. et al. High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review. J Arthroplasty. 2015 Sep; 30 (9): 1506–1512.e5. DOI: 10.1016/j.arth.2015.03.036
10. Zhao R, Wang H, Wang X, Feng F. Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis. Osteoporos Int. 2017; 28 (3): 1027–1034. DOI: 10.1007/s00198-016-3824-z
11. Chang C, Greenspan A, Gershwin ME. The pathogenesis, diagnosis and clinical manifestations of steroid-induced osteonecrosis. J Autoimmun. 2020 Jun; 110: 102460. DOI: 10.1016/j.jaut.2020.102460
12. Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020; 395 (10223): 497–506. DOI: 10.1016/S0140–6736(20)30183-5
13. Liu J, Li S, Liang B. et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020 May; 55: 102763. DOI: 10.1016/j.ebiom.2020.102763
14. Salvio G, Gianfelice C, Firmani F. et al. Bone metabolism in SARS-CoV-2 disease: possible osteoimmunology and gender implications. Clin Rev Bone Miner Metab. 2020; 18 (4): 51–57. DOI: 10.1007/s12018-020-09274-3
15. Zhang B, Zhang S. Corticosteroid-Induced Osteonecrosis in COVID-19: A Call for Caution. J Bone Miner Res. 2020; 35 (9): 1828–1829. DOI: 10.1002/jbmr.4136
16. Bejoy P, Prerona M, Yuti K. et al. COVID-19 and Its Long-Term Impact on the Cardiovascular System. Expert Rev. Cardiovasc. Ther. 2023; 21: 211–218. DOI: 10.1080/14779072.2023.2184800
17. Ingul CB, Grimsmo J, Mecinaj A. et al. Cardiac dysfunction and arrhythmias 3 months after hospitalization for COVID-19. J Am Heart Assoc. 2022; 11 (3): e023473. DOI: 10.1161/JAHA.121.023473
18. Bisaccia G, Ricci F, Recce V. et al. Post-acute sequelae of COVID-19 and cardiovascular autonomic dysfunction: what do we know? J Cardiovasc Dev Dis. 2021; 8 (11): 156. DOI: 10.3390/jcdd8110156
19. Soewono KY, Raney KC, Sidhu MS. Pericarditis with pericardial effusion as a delayed complication of COVID-19. Proc (Bayl Univ Med Cent). 2021; 34 (5): 629–630. DOI: 10.1080/08998280.2021.1918975
20. Dini FL, Baldini U, Bytyçi I, et al. Acute pericarditis as a major clinical manifestation of long COVID-19 syndrome. Int J Cardiol. 2023 Mar 1; 374: 129–134. DOI: 10.1016/j.ijcard.2022.12.019
21. Puntmann VO, Carerj ML, Wieters I. et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered from Coronavirus Disease 2019 (COVID-19) JAMA Cardiol. 2020; 5: 1265–1273. DOI: 10.1001/jamacardio.2020.3557
22. Moody WE, Liu B, Mahmoud-Elsayed HM. et al. Persisting Adverse Ventricular Remodeling in COVID-19 Survivors: A Longitudinal Echocardiographic Study. J. Am. Soc. Echocardiogr. 2021; 34: 562–566. DOI: 10.1016/j.echo.2021.01.020
23. Alkodaymi MS, Omrani OA, Fawzy NA. et al. Prevalence of Post-Acute COVID-19 Syndrome Symptoms at Different Follow-up Periods: A Systematic Review and Meta-Analysis. Clin. Microbiol. Infect. 2022; 28: 657–666. DOI: 10.1016/j.cmi.2022.01.014
24. Al-Khadra Y, Darmoch F, Moussa Pacha H. et al. P5341 Autoimmune disease association with pericar dial diseases: An analysis of the national inpatient sample. Eur Heart J. 2018; 39 (Suppl 1): ehy566.P5341. DOI: 10.1093/eurheartj/ehy566.P5341
25. Belov B. S., Tarasova G. M. Pericarditis in rheumatology: modern clinical and diagnostic aspects and treatment aspects. Consilium Medicum. 2020; 22 (1): 26–30. (In Russ.). DOI: 10.26442/20751753.2020.1.200060
26. Dzhuzenova B. S., Kotelnikova G. P., Mikhailova I. N., Nasonova V. A. Acute rheumatic carditis in young men. Ther. archive. 1992; 4: 58–62. (In Russ.).
27. Medyntseva L. G. Physical performance of children with rheumatism at the stage of medical examination: Abstract of Cand. Sci. (Med.) dissertation. Moscow, 1990. (In Russ.).
28. Long Q, Li J, Hu X. et al. Follow-Ups on Persistent Symptoms and Pulmonary Function Among Post-Acute COVID-19 Patients: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2021; 8: 702635. DOI: 10.3389/fmed.2021.702635
29. Cares-Marambio K, Montenegro-Jiménez Y. et al. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Chron Respir Dis. 2021; 18: 14799731211002240. DOI: 10.1177/14799731211002240
30. Dani M, Dirksen A, Taraborrelli P. et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin med (Lond). 2021; 21 (1): e63–e67. DOI: 10.7861/clinmed.2020–0896
31. Duong-Quy S, Vo-Pham-Minh T, Tran-Xuan Q. et al. Post-COVID-19 Pulmonary Fibrosis: Facts-Challenges and Futures: A Narrative Review. Pulm Ther. 2023; 9 (3): 295–307. DOI: 10.1007/s41030–023–00226-y. Epub 2023 May 20.
32. Guinto E, Gerayeli FV, Eddy RL. et al. Post-COVID-19 dyspnoea and pulmonary imaging: a systematic review and meta-analysis. Eur Respir Rev. 2023; 32 (169): 220253. DOI: 10.1183/16000617.0253-2022
33. Wu X., Liu X., Zhou Y. et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021; 9 (7): 747–754. DOI: 10.1016/S2213-2600(21)00174-0
34. George PM, Barratt SL, Condliffe R. et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020; 75: 1009–1016. DOI: 10.1136/thoraxjnl-2020-215314
35. Guidelines «Characteristics of the course of long-COVID infection. Therapeutic and rehabilitation measures.” Therapy. 2022; 1 (Supplement): 1–147. (In Russ.). https://dx.doi.org/10.18565/therapy.2022.1suppl.1-147
36. Recalcati S. Кожные проявления при COVID-19: первая точка зрения. J Eur Acad Dermatol Venereol. 2020; 34 (5): e212–e213. DOI: 10.1111/jdv.16387
37. Desai AD, Lavelle M, Boursiquot BC, Wan EY. Long-term complications of COVID-19. Am J Physiol Cell Physiol. 2022; 322 (1): C 1–C 11. DOI: 10.1152/ajpcell.00375.2021
38. McGonagle D, Bridgewood C, Ramanan AV, et al. COVID-19 vasculitis and novel vasculitis mimics. Lancet Rheumatol. 2021; 3 (3): e224–e233. DOI: 10.1016/S2665-9913(20)30420-3
39. Rocha KO, Zanuncio VV, Freitas BAC, Lima LM. «COVID toes»: A meta-analysis of case and observational studies on clinical, histopathological, and laboratory findings. Pediatr Dermatol. 2021; 38 (5): 1143–1149. DOI: 10.1111/pde.14805
40. Mehta P, Bunker CB, Ciurtin C. et al. Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy. Lancet Infect Dis. 2021; 21 (7): 912. DOI: 10.1016/S1473-3099(21)00133-X
41. Chaudhary H, Mohan M, Jain A. et al. Acral Gangrene: Ugly Cousin of «COVID Toes» in Multisystem Inflammatory Syndrome in Children Associated with SARS-CoV-2? Pediatr Infect Dis J. 2021; 40 (8): e312–e313. DOI: 10.1097/INF.0000000000003181
42. Casas G, Català A, Hernández C. et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020; 183 (1): 71–77. DOI: 10.1111/bjd.19163
43. Perna A, Passiatore M, Massaro A. et al. Skin manifestations in COVID-19 patients, state of the art. A systematic review. Int J Dermatol. 2021; 60 (5): 547–553. DOI: 10.1111/ijd.15414
44. McMahon DE, Gallman AE, Hruza GJ. et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. Lancet Infect Dis. 2021; 21 (3): 313–314. DOI: 10.1016/S1473-3099(20)30986-5
45. Chularojanamontri L, Tuchinda P, Rujitharanawong C. et al. New-onset and exacerbated skin diseases after COVID-19 infection: a systematic review. J Dermatol. 2022; 49 (11): e419–e421. DOI: 10.1111/1346-8138.16501
46. Shanshal M. COVID-19 related anagen effluvium. J Dermatolog Treat. 2022; 33 (2): 1114–1115. DOI: 10.1080/09546634.2020.1792400
47. Aksoy H, Yıldırım UM, Ergen P, Gürel MS. COVID-19 induced telogen effluvium. Dermatol Ther. 2021; 34 (6): e15175–e15175. DOI: 10.1111/dth.15175
48. Wambier CG, Vaño-Galván S, McCoy J., et al. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: the «Gabrin sign». J Am Acad Dermatol. 2020; 83 (2): 680–682. DOI: 10.1016/j.jaad.2020.05.079
Review
For citations:
Aronova E.S., Belov B.S., Gridneva G.I. Postcovoid syndrome from the perspective of a rheumatologist: problems of differential diagnosis. Medical alphabet. 2025;(9):32-36. (In Russ.) https://doi.org/10.33667/2078-5631-2025-9-32-36
Views:
63
Email this article 